Abilify is a brand name of aripiprazole, approved by the FDA in the following formulation(s):
ABILIFY (aripiprazole - injectable; intramuscular)
Manufacturer: OTSUKA
Approval date: September 20, 2006
Strength(s): 9.75MG/1.3ML (7.5MG/ML) [RLD]
ABILIFY (aripiprazole - solution; oral)
Manufacturer: OTSUKA
Approval date: December 10, 2004
Strength(s): 1MG/ML [RLD]
ABILIFY (aripiprazole - tablet, orally disintegrating; oral)
Manufacturer: OTSUKA
Approval date: June 7, 2006
Strength(s): 10MG [RLD], 15MG
ABILIFY (aripiprazole - tablet; oral)
Manufacturer: OTSUKA
Approval date: November 15, 2002
Strength(s): 10MG [RLD], 15MG, 20MG, 2MG, 30MG, 5MG [RLD]
Has a generic version of Abilify been approved?
No. There is currently no therapeutically equivalent version of Abilify available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Abilify. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Carbostyril derivatives
Patent 5,006,528
Issued: April 9, 1991
Inventor(s): Oshiro; Yasuo & Sato; Seiji & Kurahashi; Nobuyuki
Assignee(s): Otsuka Pharmaceutical Co., Ltd.
A novel carbostyril derivative and salt thereof represented by the formula (1) ##STR1## (wherein R is a group of the formula ##STR2## ((wherein R.sup.1 is a C.sub.1- C.sub.3 alkoxy group)), a group of the formula ##STR3## ((wherein R.sup.2 and R .sup.3 are each, at the same time, a chlorine atom, a bromine atom; and R.sup.4 is a hydrogen atom or a chlorine atom)), 2-methyl-3-nitrophenyl group, 3,5-dichlorophenyl group, or a group of the formula ##STR4## ((wherein R.sup.5 is a chlorine atom or a bromine atom; and R.sup.6 is a methyl group)); the carbon-carbon bond between 3- and 4-position in the carbostyril skeleton is a single or double bond).
Patent expiration dates:
Aripiprazole oral solution
Patent 6,977,257
Issued: December 20, 2005
Inventor(s): Parab; Prakash V. & Chou; Joyc Tianw i
Assignee(s): Bristol-Myers Squibb Company
The present invention provides for a pharmaceutical solution suitable for oral administration comprising aripiprazole, a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents and one or more agents selected from the group consisting of lactic acid, acetic acid, tartaric acid and citric acid, wherein said solution has a pH from 2.5 to 4.5.
Patent expiration dates:
- April 24, 2022
✓
Drug substance
✓
Drug product
- October 24, 2022
✓
Pediatric exclusivity
Aripiprazole complex formulation and method
Patent 7,115,587
Issued: October 3, 2006
Inventor(s): Nerurkar; Manoj & Naringrekar; Vijay
Assignee(s): Bristol-Myers Squibb Company
An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
Patent expiration dates:
Aripiprazole complex formulation and method
Patent 7,550,445
Issued: June 23, 2009
Inventor(s): Nerurkar; Manoj & Naringrekar; Vijay
Assignee(s): Bristol-Myers Squibb Company
An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
Patent expiration dates:
- July 21, 2024
✓
Drug product
- January 21, 2025
✓
Pediatric exclusivity
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
See also...
- Abilify Consumer Information (Drugs.com)
- Abilify Consumer Information (Wolters Kluwer)
- Abilify Solution Consumer Information (Wolters Kluwer)
- Abilify Tablets Consumer Information (Wolters Kluwer)
- Abilify Consumer Information (Cerner Multum)
- Abilify Advanced Consumer Information (Micromedex)
- Abilify Intramuscular Advanced Consumer Information (Micromedex)
- Abilify AHFS DI Monographs (ASHP)
- Aripiprazole Consumer Information (Wolters Kluwer)
- Aripiprazole Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
- Aripiprazole Solution Consumer Information (Wolters Kluwer)
- Aripiprazole Tablets Consumer Information (Wolters Kluwer)
- Aripiprazole Consumer Information (Cerner Multum)
- Aripiprazole Advanced Consumer Information (Micromedex)
- Aripiprazole Intramuscular Advanced Consumer Information (Micromedex)
- Aripiprazole AHFS DI Monographs (ASHP)
